Vinay Yadav

About

Doctorate with several years of experience Cancer genomics expert with a background in genomics and functional genomics for 6 years in academia, and in the industry.

• Productive and independent oncology research professional with excellent teamwork skills
• Excellent project management and leadership skills in communicating with interdisciplinary groups
• Experienced in building and maintaining partnerships, and cross-sectional teamwork between academic and industry professionals in both clinical and non-clinical settings
• Well-versed with next-generation sequencing (NGS)-based commercial oncology assay development pipeline as per CLIA, FDA & CAP standards.
• Open to learning new skills in science policy, science communication, and career development as well as sharing the knowledge with the border scientific community by conducting webinars.

My passion is to translate genomic discoveries into clinical settings by discovering, developing, and implementing next-generation sequencing-based molecular assays for oncology and immunological diseases. As a biomedical researcher, I am dedicated to advancing genomic discoveries into clinical practices by working at the interface of academics and industry to reduce the barriers of translational research in oncology by dovetailing bench work, and computational, clinical, and industrial experience skills.

I am also highly enthusiastic about exploring a new arena of science policy, science communication, and career development in the area of cancer therapeutics.

Employment

• MedGenome Inc Senior Genome Analyst
  2022 - Present
• Industrial Toxicology Research Centre RESEARCH
  2016 - 2022

Education

• Industrial Toxicology Research Centre Ph.D
  2016 - 2022

Projects & Funding

Projects & funding information is unavailable.

Publications (7)

• Correlation of Anemia with Glycated Hemoglobin among Euglycemic Type 2 Diabetic Patients.
  The Journal of the Association of Physicians of India 2023 DOI: 10.5005/japi-11001-0201
  +Save
• Interaction of cytochrome P450s with environmental risk factors increases their expression and risk to head and neck cancer.
  Environmental and molecular mutagenesis 2022 DOI: 10.1002/em.22495
  +Save
• Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome.
  Environmental and molecular mutagenesis 2021 DOI: 10.1002/em.22466
  +Save
• Interaction of glutathione-s-transferase genotypes with environmental risk factors in determining susceptibility to head and neck cancer and treatment response and survival outcome.
  Environmental and molecular mutagenesis 2020 DOI: 10.1002/em.22362
  +Save
• Validation of gene expression profiles of candidate genes using low density array in peripheral blood of tobacco consuming head and neck cancer patients and auto/taxi drivers with preneoplastic lesions
  Genomics 2020 DOI: 10.1016/j.ygeno.2019.04.003
  +Save
• Similarities in mRNA expression of peripheral blood drug metabolizing enzymes and cancer marker genes with biopsy samples of head and neck cancer patients.
  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2019 DOI: 10.1080/1354750x.2019.1609090
  +Save
• CYP2C9 polymorphisms: considerations in NSAID therapy.
  Current opinion in drug discovery & development 2009
  +Save